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Summary 
Objectives: We aimed to assess infection control rates after DAIR in patients with periprosthetic joint 
infection (PJI) following joint arthroplasty and evaluate factors associated with infection control using 
a systematic review and meta-analysis.  
Methods: We searched MEDLINE, EMBASE, Web of Science, Cochrane databases and reference 
lists of relevant studies up to May 2017. Longitudinal studies conducted in patients with PJI treated 
exclusively by DAIR were eligible. Infection control rates were meta-analysed using random-effect 
models after arcsine transformation. 
Results: We included 93 articles based on 99 unique observational studies with data on 4897 PJIs 
treated by DAIR. The infection control rate for DAIR ranged from 11.1% to 100% with an overall 
pooled estimate of 61.4% (95% CI, 57.3-65.4) and a 95% prediction interval of 25.5 to 91.8%. 
Infection control rates remained generally similar for several relevant characteristics, except for 
evidence of variation by age, geographical location, type of infection and joint affected, duration of 
parenteral antibiotic therapy after the DAIR procedure, and period (year) of DAIR procedure.  
Conclusions: The DAIR approach remains an option for the treatment of PJI as it is associated with 
acceptable infection control rates, particularly in acute postoperative infections and infections of the 
hip and shoulder joints. 
 
Systematic review registration: PROSPERO 2017: CRD 42017057513 
Key words: periprosthetic joint infection; total joint arthroplasty; debridement, antibiotics and 
implant retention; infection control; systematic review, meta-analysis 
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Introduction 
Total joint arthroplasty, which is one of the most common surgical procedures, is an effective 
intervention for alleviating the pain and disability associated with advanced joint disease.(1-4) The 
numbers of total joint arthroplasties is projected to increase,(5-7) as a result of increasing life 
expectancy and a subsequently growing healthcare burden due to osteoarthritis and other joint 
conditions associated with ageing.(8) Periprosthetic joint infections (PJIs) though uncommon, are 
serious and devastating complications of total joint arthroplasties.(9, 10) Periprosthetic joint infections 
have major negative effects on patients’ quality of life(11-13) and can result in severe pain, impaired 
function, and even death if left untreated.(14) Treatment options for PJI include long-term suppressive 
antibiotic treatment which is generally reserved for patients who are not suitable for surgery due to 
comorbidities;(15) debridement, antibiotics and implant retention (DAIR); one- or two-stage revision; 
and resection arthroplasty. Arthrodesis or amputation is normally considered as a last resort.(16, 17) 
In the management of PJI, the immediate and long-term goals include the control of infection, 
preventing recurrence, minimizing morbidity, pain relief, and optimizing joint function.(18-21) For 
the treatment of chronic PJI, most individuals undergo revision surgery with one or two operations. In 
the more widely used two-stage revision, prosthetic components are removed with extensive 
debridement of infected tissue and delayed re-implantation of revision components after a period of 
antibiotic therapy with no prosthesis in situ or a temporary spacer or implant. Although widely used, 
the two-stage strategy involves two extensive surgical procedure and is frequently associated with 
prolonged hospitalisation, significant functional impairment, and morbidity.(22) Thus, surgical 
revision using a one-stage strategy, with removal of prosthetic components, debridement and implant 
replacement in a single operation, is increasingly being used.(23, 24) For some patients, DAIR is 
considered as an alternative option, as it involves a less extensive surgical procedure and is associated 
with a shorter hospital stay, improved joint function, and less morbidity.(20, 25)  
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The DAIR approach has been recommended for the treatment of early PJIs.(26-29) Despite published 
evidence and guidelines on the treatment of PJI using DAIR, its role and appropriateness in the 
treatment of PJI still remain controversial, as the evidence and recommendations are mostly based on 
non-randomised observational studies, case series, and/or expert opinion. Infection control rates of 
DAIR for hip and knee PJI varies in the literature and have been reported to range from as low as 0% 
to as high as 100%.(30, 31) A number of factors have also been reported to influence the success rates 
of DAIR, some of which include the type of infecting micro-organism, duration of symptoms, length 
of antibiotic use, and the period between the onset of symptoms and initiation of treatment.(32-35) 
The results of previous studies have been inconsistent and studies were often poorly powered to 
adequately quantify the infection control rates and reliably evaluate potential factors that influence 
treatment outcomes of DAIR, were based on inadequate follow-up times, and cases were sometimes a 
mix of arthroplasties of different joints. A number of reviews have also been published in an effort to 
summarise the existing evidence. In a review of 23 studies which included 530 infected total knee 
arthroplasties treated using an open DAIR approach, Silva and colleagues reported infection control in 
32.6% of the infected knees.(36) In the same review, 52.2% of 23 infected knees from four studies 
were free from infection after arthroscopic DAIR. In a narrative review of 52 studies of DAIR for 
infected total knee arthroplasty, the authors identified factors such as presence of a sinus, being 
immunocompromised, short antibiotic duration, and delay between onset of infection and debridement 
procedure, to be important contributors of failure to control infection.(28) In a review of 28 studies 
involving 599 cases of PJIs of the knee, the overall success rate after DAIR was reported to be 47%. 
Findings from this review suggested that the rate of infection remission was significantly higher in 
streptococcal knee PJIs compared with staphylococcal knee PJIs.(31) There were several features of 
these reviews which limited the validity of the findings. First, the majority of these reviews did not 
pool the evidence using appropriate meta-analytic methods, which should take into account the 
variability of the included studies. Second, none of the reviews explored for potential sources of 
heterogeneity among the contributing studies. Third, none of the reviews conducted any subgroup 
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analysis across important study-level and clinically relevant characteristics (e.g. age at baseline, the 
type of infecting micro-organism, type of joint affected, length of antibiotic use, the period between 
the onset of symptoms and initiation of treatment, follow-up period, and methodological quality 
scores of included studies). Fourth, preferential publication bias was not assessed. In addition, several 
relevant individual reports have been published since the publication of these reviews.  
 
With the current interest in the use of DAIR for treating PJI, there is a need for robust evidence on the 
effectiveness of the DAIR strategy in controlling PJI. In the absence of data from a carefully designed 
large-scale prospective study or randomised controlled trial (RCT); we aimed to use a systematic 
review and meta-analysis to (i) assess a reliable magnitude of the infection control rate after DAIR in 
patients with PJI following total joint arthroplasty and (ii) evaluate factors associated with infection 
control by assessing if infection control rates varied across several study-level and clinically relevant 
characteristics.  
 
Methods 
Data sources and search strategy 
This review is registered in the PROSPERO prospective register of systematic reviews (CRD 
42017057513), and was conducted in accordance with PRISMA and MOOSE guidelines(37, 
38)(Supplementary Materials 1-2). We systematically searched MEDLINE, EMBASE, and Web of 
Science from inception up to May 2017. The computer-based searches combined free and MeSH 
search terms and combination of key words related to DAIR, PJI, and joint arthroplasty. The search 
was restricted to studies of humans. We complemented the search by manually scanning reference 
lists of key identified articles and review articles for relevant publications missed by the original 
search. Details on our search strategy are presented in Supplementary Material 3.  
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Eligibility criteria 
We systematically searched for longitudinal studies (prospective or retrospective case control, 
prospective cohort, retrospective cohort, case-cohort, nested-case control, or clinical trials) that 
reported infection control following the use of DAIR in patients with PJI following total joint 
arthroplasty. A successful treatment outcome (infection control) was the primary endpoint of our 
review and this was defined by studies as no evidence of infection or eradication of infection based on 
clinical and laboratory confirmation or survival of the prosthesis in the absence of long-term antibiotic 
suppression or if patients did not undergo further revision procedures using other surgical procedures 
during the follow-up period. We excluded studies (i) that reported on patients who were treated by a 
variety of other surgical methods for the same infection at the same time; (ii) of any other surgical 
approach apart from total joint arthroplasty such as in the setting of fracture, hemiarthroplasty, or 
resurfacing arthroplasty; and (iii) that were restricted to patients who had undergone revision 
arthroplasty.  
 
Data extraction and quality assessment  
After the initial screen of titles and abstracts by one reviewer (S.K.K.), potentially relevant articles 
were acquired. Full texts of articles were assessed by two independent reviewers (S.K.K., A.D.B.) 
using the inclusion criteria. Any discrepancies regarding eligibility of an article were discussed, and 
consensus reached with a third author (M.R.W). One author (S.K.K.) independently extracted data 
and performed quality assessments using a standardized predesigned data collection form. A second 
reviewer checked extracted data with that in the original articles. In the case of multiple publications 
involving the same cohort, data were extracted from the most up-to-date study or study with the most 
comprehensive information was abstracted. When available, data were extracted on: publication date; 
study design; year of study/data collection; geographical location; mean or median age of patients; 
percentage of males; primary surgery; time from index surgery to onset of symptoms, diagnosis of 
PJI, and DAIR; duration of infection symptoms prior to DAIR; infection type (acute postoperative vs 
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acute haematogenous vs late chronic); main pathogen involved; DAIR approach (arthroscopic vs 
open); duration of follow-up from DAIR; sample size (number of patients or PJIs); and infection 
control after DAIR. Methodological quality of included studies was assessed based on the 
Methodological Index for Non-Randomised Studies (MINORS), a validated instrument which is 
designed for assessment of methodological quality of non-randomized studies in surgery (39) and has 
been described previously.(40) Briefly, it uses eight pre-defined domains namely: a clearly stated aim; 
inclusion of consecutive patients; prospective collection of data; endpoints appropriate to the aim of 
the study; unbiased assessment of the study endpoint; follow-up period appropriate to the aim of the 
study; loss to follow-up less than 5%; and prospective calculation of the study size. For non-
comparative studies, the total score ranges from 0 to 16 (worst to best quality).  
 
Statistical analysis 
The infection control rate (estimated from the number of infections successfully treated within follow-
up period/total number of participants with PJI or PJIs as reported) with 95% confidence intervals 
(CIs) was used as the summary measure across studies. The Freeman-Tukey variance stabilising 
double arcsine transformation (41) was used in calculating the rates, because the use of the inverse 
variance weight in fixed-effects meta-analysis is suboptimal when dealing with binary data with low 
rates, as evidenced in our data.(40) To account for the effect of between-study heterogeneity 
anticipated, summary infection control rates were pooled using random effects models (42). We also 
estimated 95% prediction intervals which are used to determine the degree of heterogeneity, as they 
provide a region in which about 95% of the true effects of a new study are expected to be found.(43, 
44) Standard chi-square tests and the I2 statistic (45) were used to quantify the extent of statistical 
heterogeneity across studies. We assessed for heterogeneity by several study-level characteristics 
using stratified analysis and random effects meta-regression.(46) We also evaluated for publication 
bias using Egger’s regression symmetry tests.(47) STATA release 14 (Stata Corp, College Station, 
Texas, USA) was used for all statistical analyses. 
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Results 
Study identification and selection 
Our search identified 2557 potentially relevant citations. After an initial screen based on titles and 
abstracts, we selected 157 articles for full text evaluation. Following detailed assessments, 64 articles 
were excluded because (i) they were duplicates or used the same population sample as other studies 
included in the review (n=22); (ii) the populations used were not relevant to review (n=20); (iii) the 
surgical interventions used were not relevant (n=8); (iv) they were conference publications (n=6); (v) 
outcomes were not relevant to review (n=5); or (vi) the study designs were not relevant (n=3). The 
remaining 93 articles based on 99 unique observational studies met all inclusion criteria and were 
included in the review (Fig. 1; Supplementary Materials 4-5).  
 
Study characteristics and study quality 
Table 1 provides a summary of baseline and clinical characteristics of studies included in the review. 
Supplementary Material 5 summarizes the key characteristics and quality assessment scores of the 
individual studies. In aggregate, 4897 PJIs were included in the pooled analysis. Sample size of the 
studies ranged from 3 to 345 joints with PJIs. A total of 40 studies were conducted in North America 
(USA); 36 in Europe (Netherlands, Switzerland, Spain, Slovenia, UK, Finland, Norway, Denmark, 
Sweden, Italy, France, and Germany); 10 in Asia (Taiwan, Japan, South Korea, and China); six in the 
Pacific (Australia and New Zealand); and one in South America (Brazil). The mean or median 
baseline age of participants ranged from 55 to 80 years. All eligible studies were longitudinal 
observational studies and comprised of 82 retrospective and 11 prospective cohort designs. The 
average follow-up duration after DAIR ranged from 1.0 to 7.1 years. Methodological quality of 
included studies ranged from 10-14.   
 
 
 
  
9 
 
Infection control rate after DAIR 
Across the 93 eligible studies comprising of 4897 PJI infections treated with DAIR, infection control 
rates ranged from 11.1% to 100%. The pooled random effects infection control rate (95% CI) was 
61.4% (57.3-65.4; p < 0.01) (Fig. 2). The 95% prediction interval for the summary infection control 
rate was 25.5 to 91.8%, suggesting that the true infection control rate for any single new study will 
usually fall within this range. There was substantial heterogeneity between contributing studies 
(I2=86%, 95% CI: 84-88%; p < 0.01), which was partly explained by geographical location, average 
baseline age, type of infection, type of joint affected, duration of parenteral antibiotic therapy after the 
DAIR procedure, and period of DAIR procedure (Fig. 3). In further exploration of heterogeneity, we 
restricted analyses to studies of hip and knee joints and this substantially reduced heterogeneity to 
(I2=59%, 95% CI: 29-76%; p < 0.01). Among these studies, the pooled infection control rate (95% CI) 
was 75.4% (69.6-80.9; p < 0.01) with a 95% prediction interval of 54.4 to 91.9%. 
 
Subgroup analyses 
Except for statistically significant evidence of variation by geographical location (p for meta-
regression<0.001), average baseline age (p for meta-regression=0.022), type of infection (acute vs 
chronic) (p for meta-regression=0.012), joint type (p for meta-regression<0.001), duration of 
parenteral antibiotic therapy after DAIR ((p for meta-regression=0.01), and period of DAIR procedure 
for all joint types (p for meta-regression=0.020), infection control rates were generally similar across 
several study relevant characteristics (Fig. 3). Infection control was higher in older individuals (≥ 70 
years) compared to less older individuals (< 70 years). Higher infection control rates were observed in 
patient populations based in Europe, the Pacific, and South America compared with those in Asia and 
North America and in acute infections (acute postoperative and haematogenous) compared with late 
chronic infections. In subgroup analysis by joint type, DAIR was associated with higher infection 
control in hip, elbow, and shoulder joints compared with knee joints. Patients administered parenteral 
antibiotics for a period of ≤ 14 days after DAIR had higher infection control compared with those who 
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received parenteral antibiotics for > 14 days. Infection control was higher for DAIRs conducted in the 
period 2000 and beyond compared to those conducted before the year 2000 in all joint types. 
However, in sub-analysis by joint type, there was no statistically significant evidence of any 
variations in infection control by period of DAIR procedure in both hip and knee infections. 
Recognising that infections occurring within two years of the intervention are mainly as a 
consequence of the surgical intervention,(48, 49) we also conducted subgroup analysis by follow-up 
period after DAIR (≤ 2 vs > 2 years) and we observed infection control rates to be similar across both 
groups (p for meta-regression = 0.602) (Fig. 3).  
 
Publication bias 
There was no statistically significant evidence of publication bias using the Egger test (p=0.858), 
which was consistent with the absence of selective reporting when studies were grouped by size (Fig. 
3). 
 
Discussion 
Key findings 
Given the uncertain role of DAIR and its appropriateness in the treatment of PJI, using a systematic 
and meta-analytical approach, we attempted to obtain a precise magnitude of infection control rates 
after DAIR in patients with PJI following joint arthroplasty and assess if infection control rates varied 
across several relevant clinical factors. We included data on 99 unique observational studies based on 
patients with PJI recruited from five continents. Based on individual study findings, infection control 
rates ranged from 11% to 100% and averaged approximately 61% in pooled analysis. When analysis 
was restricted to hip and knee joints, the average infection control rate was 75.4%. The infection 
control rates were generally similar across several study level and clinically relevant characteristics 
such as specific infecting organism, DAIR approach, duration of follow-up, methodological quality of 
studies, and period of DAIR procedure for hip and knee joints; except for evidence of variation by 
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geographical location, age, infection type, joint type, duration of parenteral antibiotic therapy after 
DAIR, and period of DAIR procedure for all joint types. Infection control rates were higher in patient 
populations based in Europe, the Pacific, and South America compared with those in Asia and North 
America; in older patients compared with less older patients; in acute infections compared with late 
chronic infections; in hip, elbow, and shoulder joints compared with knee joints; in patients 
administered parenteral antibiotics for a period of 14 days and less after DAIR compared with those 
who received parenteral antibiotics for more than 14 days; and in patient populations who had a DAIR 
in 2000 and beyond compared to those who had the procedure before the year 2000. 
 
Comparison with previous work and explanation of findings 
Though a number of reviews have been conducted on the topic and our findings do overlap with some 
of these previous reports; our review provides several novel and relevant findings that have not been 
reported previously. By employing statistical approaches, our findings suggest that factors such as the 
geographical location, baseline age, type of infection, type of joint affected, duration of parenteral 
antibiotic therapy, and year in which DAIR was performed, may influence infection control after the 
procedure. Though a previous study found no substantial difference in infection control with DAIR 
comparing > 3 weeks with < 3 weeks duration of symptoms;(50) our results show that a longer 
duration between onset of symptoms to DAIR (≥ 21 days) is associated with lower infection control 
compared with a shorter duration (< 21 days), though the test of interaction was marginally 
significant. Our results concur with evidence which shows that the duration of symptoms is an 
important factor for successful infection control in DAIR(48, 51) along with previous 
recommendations that suggest a DAIR approach is likely to be successful for the treatment of early 
infections if the duration does not exceed three weeks.(48) The statistically nonsignificant result may 
indicate low power in the subgroup analysis. In a narrative review of 52 studies of DAIR for infected 
total knee arthroplasty, Qasim and colleagues suggested that factors such as presence of a sinus, 
compromised immunity, delay between onset of infection and debridement procedure, short antibiotic 
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duration, and an open debridement procedure, to be important contributors of treatment failure.(28) 
Contrary to the findings of Qasim et al.,(28) we showed that shorter compared with longer parenteral 
antibiotic duration was associated with higher infection control. In our analysis by DAIR type, 
infection control rates were 60.3% and 71.8% for open and arthroscopic DAIR respectively, though 
the difference was not statistically significant. Silva and colleagues reported an infection control rate 
of 32.6% in a review of 23 studies including infected total knee arthroplasty treated with open DAIR; 
whilst in the same study, they reported an infection control rate of 52.2% in pooled analysis of four 
studies of infected knee arthroplasty treated with arthroscopic DAIR.(36) In a review of 28 studies of 
knee PJIs treated by DAIR, infection control averaged 47% and infection remission was higher for 
streptococcal compared with staphylococcal PJIs.(31) Findings from our analyses by specific 
infecting organism suggested similar infection control for Gram negative and Gram positive 
organisms and further analysis confirmed higher infection control for streptococcal infection (89.5%) 
compared with staphylococcal species (75.2%). Indeed, Staphylococcus aureus infection, particularly 
Methicillin-resistant Staphylococcus aureus (MRSA), has been shown to be associated with high 
failure rates after DAIR.(20, 52, 53) Consistent with the literature,(36, 54, 55)  our findings confirmed 
higher infection control in acute postoperative infections compared with acute haematogenous and 
late chronic infections using the DAIR approach. Furthermore, our study findings demonstrated that 
when comparing the two most common joints, infection control was higher for infected hip 
arthroplasty (75.4%) compared with infected knee arthroplasty (52.6%). The finding of higher 
infection control with DAIR in European populations compared with North American populations, 
may reflect the fact that DAIR is more commonly used in Europe for treating PJI whilst a two-stage 
strategy is traditionally used in the USA.(50) The higher infection control rate observed in older 
individuals, may also reflect the fact that the elderly are less likely to be subjected to more invasive 
surgical procedures compared with less older individuals; and since some studies define treatment 
failure following DAIR as a further revision procedure using other surgical procedures, younger 
individuals are more likely to be reported as having a treatment failure compared with their older 
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counterparts. Finally, we observed higher infection control for DAIRs done in the year 2000 and 
beyond compared to DAIRs performed in the 1980’s and 1990’s, perhaps reflecting improved surgical 
strategies and newer and more effective antimicrobial therapies in recent times. There was also a trend 
towards more favourable infection control rates for DAIR procedures in knee PJI performed in the 
year 2000 and beyond compared to those conducted before the year 2000. The significantly better 
infection control with a shorter duration of antibiotics following intervention may represent selection 
for these particular strategies on the basis of the severity of the presenting PJI or the adequacy of 
control of the PJI at the DAIR procedure. 
 
Implications of our findings 
The current findings provide further insight on infection control using the DAIR approach, which may 
have implications for the treatment of PJI. Overall, the findings do demonstrate that the DAIR 
procedure is an effective treatment option for the majority of PJIs. Although, in the majority of cases, 
DAIR is effective in treating PJI; one- and two-stage revision for infection following hip and knee 
replacement results in higher infection control rates. Systematic review and meta-analyses of data 
from cohort studies show infection eradication of 91.8% in one-stage revision for infected hip 
replacement, 92.1% in two-stage revision for infected hip replacement,(56) 92.4% in one-stage 
revision for infected knee replacement, and 91.2% in two-stage revision for infected knee 
replacement.(57) This higher rate of infection eradication needs to be balanced against the burden(11, 
13) and risk of undergoing much more radical and invasive surgery. In the absence of RCTs 
comparing DAIR with revision surgery, it appears the results from aggregate data of cohort studies 
suggest inferior infection control rates compared to those achieved with one- or two-stage revision. 
However, DAIR is a far less invasive procedure and does not preclude subsequent revision surgery. It 
may be that an optimal treatment algorithm includes DAIR followed by implant revision in cases 
where the DAIR proves to be unsuccessful. DAIR has generally been the recommended treatment in 
patients with acute infections in a previously well-functioning prosthesis that is not loose, infections 
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caused by low virulent organisms, and patients who are not immunocompromised.(58-60) Indeed, our 
findings showed that patients with acute postoperative infections had better infection control. 
Paradoxically, Staphylococcus aureus commonly accounts for most acute postoperative infections and 
are also associated with comparatively higher failure rates after DAIR. (20, 52, 53) Zurcher-Pfund et 
al. and others recommend that the implant should not be retained in MRSA infections in addition to 
established indications such as presence of a sinus tract as well as implant loosening.(28, 31) As 
observed in previous reports,(28) a delay between onset of infection and DAIR procedure is 
associated with low infection control, and should be taken into account when considering performing 
a DAIR. Though our findings do suggest a higher infection control rate for arthroscopic debridement 
when compared with open debridement, the results were not significantly different and the pooled 
infection control rate for arthroscopic DAIR was based on only few studies. Though DAIR is 
associated with good infection control in both hip and knee joints, the current evidence suggests that 
infection control rates are better for hip joints and this needs to be taken into account when selecting 
the most appropriate intervention for a particular joint. Our findings of higher infection control with 
shorter duration of parenteral antibiotic therapy may seem unexpected; however, this may be plausible 
as several studies have demonstrated no differences in infection control when comparing shorter 
duration with longer duration of antibiotics post-procedure(61, 62) and other studies have also shown 
that prolonged parenteral antibiotic therapy does not guarantee improved infection control.(35, 59, 63) 
Current guidelines suggest 4-6 weeks of pathogen-specific intravenous antimicrobial therapy.(29) 
Based on previous data(64) and our current findings, switching from parenteral to oral antibiotics at 
an early stage post-DAIR may be as effective as prolonged parenteral therapy if not more effective. 
Nevertheless, duration of parenteral antibiotics may also depend on the virulence of the infecting 
micro-organism and adequate bone penetration, which varies between antibiotics. Furthermore, there 
is a possibility that our findings may be due to selection bias, as duration of parenteral antibiotics also 
depend on response of PJI to treatment; antibiotics are stopped in patients who recover well, whereas 
parenteral antibiotics are continued in patients with persistent symptoms and/or signs of infection. 
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Study strengths and limitations 
The current review has several strengths compared with previous reviews. To our knowledge, it is the 
most comprehensive and up to date assessment of the role of DAIR in treating PJIs. We implemented 
a search strategy across several databases as well as a manual scan of key relevant reviews on the 
topic, which yielded 93 published articles from five continents. Using a well-known validated 
instrument for non-randomised surgical studies, we conducted a detailed assessment of the 
methodological quality of the included studies. Unlike previous reviews, we employed a meta-
analytic approach across studies, which yielded a pooled estimate of infection control. Furthermore, 
our approach took into account the heterogeneity between contributing studies and ensured that 
studies with zero rates were not excluded from the pooled analysis. We compared infection control 
among a broad range of study-level and clinically relevant characteristics. Our analysis suggested no 
significant difference in infection control rates between low- and high-quality studies. Finally, we 
quantified heterogeneity and explored for potential sources of bias, which included heterogeneity and 
small study effects. We found no evidence of publication bias. There were several limitations that 
deserve consideration. The majority of studies did not distinguish between primary and revision 
arthroplasty cases, therefore it is not possible to differentiate between the two in terms of infection 
control. The retrospective designs of the majority of included studies in this review introduces biases 
because of the risk of selection bias, errors or incomplete information. The definition of a successful 
treatment outcome was not consistent across studies and infection control estimates were extracted as 
reported by the included studies, which could have introduced the possibility of biases in the 
estimates. This is particularly important because persistence of infection requiring a further DAIR 
may be considered as a failure in some studies, whereas repeat DAIR is actually part of the treatment 
protocol in some centres and not considered a failure.(65) Another major limitation was that majority 
of studies did not make it clear whether DAIR was performed with or without modular exchange, 
making it impossible to take this into account in our analyses. In one of the largest studies reporting 
treatment outcomes following the DAIR procedure in hip PJI, exchanging the modular components 
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was reported to be associated with about a 4-fold chance of infection eradication.(65) We were also 
unable to assess infection control rates across other relevant clinical characteristics such as sex, 
comorbidities, and whether single or repeat DAIR procedures were performed in patients, because of 
the lack of appropriate data in contributing studies. Given the substantial heterogeneity among the 
contributing studies, it was arguable whether a summary estimate should be presented. However, in 
addition to the summary estimate, we have also reported estimates for relevant subgroups, some of 
which explained the heterogeneity in our findings. Finally, we were unable to report other outcomes 
relevant to PJI treatment such as patient function, treatment-associated complications, and quality of 
life, as these were either not reported by contributing studies or there was lack of consistent reporting. 
 
Conclusions 
The overall evidence suggests that the DAIR approach is an effective option for the treatment of PJI in 
the majority of cases. DAIR is particularly efficacious in treating acute postoperative infections; 
infections of the hip and shoulder joints; as well as with a shorter duration of parenteral antibiotics after 
the procedure. Given that DAIR has advantages such as the potential for patients to return quickly to 
acceptable functional activity, lower morbidity, is well tolerated, and costs less for the health system, 
its use should be considered in the treatment of PJI. 
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Figure Legends 
 
Figure 1. Selection of studies included in the meta-analysis 
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Figure 2. Infection control rates in eligible studies 
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Figure 3. Infection control rates in eligible studies, grouped according to several study level 
characteristics 
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1,328
1,645
2,686
287
1338
301
1304
246
72
407
212
125
286
Infections
Controlled†
1,839
2,515
367
164
12
2,076
1,735
996
1217
53
13
1037
234
119
304
461
62
443
46
496
393
1,832
605
531
2,712
72
408
699
281
3,107
808
2,195
2,702
4,403
494
2113
618
2073
346
91
559
377
299
525
Total†
52.00 (46.00, 58.10)
69.50 (64.30, 74.50)
56.70 (45.70, 67.30)
78.20 (66.00, 88.50)
75.00 (46.80, 91.10)
67.00 (62.00, 71.80)
60.20 (53.50, 66.80)
75.40 (68.90, 81.50)
52.60 (45.10, 60.10)
69.30 (36.30, 94.70)
80.70 (51.10, 99.50)
67.70 (59.60, 75.50)
52.70 (40.80, 64.50)
31.90 (8.50, 60.20)
65.80 (51.60, 78.90)
62.00 (48.80, 74.30)
60.20 (47.50, 72.30)
56.50 (41.70, 70.70)
39.10 (25.10, 53.90)
61.70 (55.40, 67.80)
42.80 (20.70, 66.40)
65.10 (59.60, 70.50)
61.90 (52.10, 71.30)
70.50 (61.10, 79.10)
60.30 (54.90, 65.60)
71.80 (47.50, 91.40)
71.50 (53.90, 86.40)
52.90 (41.00, 64.70)
75.70 (69.90, 81.10)
62.80 (57.90, 67.70)
56.30 (43.30, 68.80)
61.60 (52.60, 70.20)
61.40 (56.60, 66.10)
61.20 (56.90, 65.40)
63.40 (50.10, 75.90)
65.00 (60.30, 69.60)
51.50 (40.40, 62.50)
63.50 (56.10, 70.60)
75.20 (65.20, 84.10)
82.40 (68.90, 93.00)
73.30 (62.50, 83.00)
56.00 (45.70, 66.10)
46.00 (30.90, 61.50)
58.60 (45.10, 71.50)
Infection control (95% CI)
< 0.001
0.022
< 0.001
0.012
0.905
0.165
0.071
0.206
0.170
0.01
0.602
0.938
0.831
0.028
0.788
0.261
P-value*
0 20 40 60 80 100
Infection control rate (%)
 
The summary estimates presented were calculated using random effects models; ATBs, antibiotics; 
CI, confidence interval (bars); DAIR, debridement, antibiotics and implant retention; *, P-value for 
meta-regression; †, total numbers for the subgroups do not add up to the overall total because of 
missing data in some studies 
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Table 1. Summary Characteristics of Included Studies Comprising of Participants With PJI and Treated With 
DAIR 
 
Characteristics  
Participants N participants or infections 
Total number that achieved infection control 2,973 
Total number of patients or infections 4,897 
Study characteristics  
Location N studies (N participants or infections) 
    North America 40 (1,839) 
    Europe 36 (2,515) 
    Asia 10 (367) 
    Pacific 6 (164) 
    South America 1 (12) 
Study design N studies 
    Retrospective cohorts 82 
    Prospective cohorts 11 
Mean (SD) follow-up (years) 3.6 (1.5) 
Study level participant characteristics  
Mean (SD) age, years 68.1 (6.0) 
Median (IQR) males, % 46 (38-52) 
Joint type* N participants or infections 
    Hip and knee 2,387 
    Knee 1,217 
    Hip 996 
    Hip, knee, shoulder, and elbow 174 
    Elbow 53 
    Shoulders 13 
    Hip, knee, and elbow 12 
Characteristics of infection and procedure  
Median (IQR) time from index surgery to onset of symptoms, weeks 11.3 (4.0-104.3) 
Median (IQR) time from index surgery to infection diagnosis, days 19.5 (16.4-495.7) 
Median (IQR) time from index surgery to DAIR, days 91.7 (25.0-520.1) 
Median (IQR) time from onset of symptoms to DAIR, days 8.4 (5.0-13.7) 
Median (IQR) duration of parenteral antibiotics after DAIR, days 28 (14-37) 
Specific infecting organism as reported in the eligible studies* N participants or infections 
    Staphylococcus aureus 443 
    Gram negative 292 
    Gram positive 180 
    Staphylococcus species 176 
    Methicillin resistant Staphylococcus aureus 62 
    Methicillin resistant Gram positive 47 
    Methicillin sensitive Gram positive 39 
    Streptococcus 19 
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    Pseudomonas aeruginosa 12 
    Mixed polymicrobial 7 
Infection type* N participants or infections 
    Acute postoperative 1,037 
    Acute haematogenous 234 
    Late chronic 119 
Debridement type* N participants or infections 
    Open 2,712 
    Arthroscopic or open 408 
    Arthroscopic 72 
Mean (range) of study quality 12 (10-14) 
 
DAIR, debridement, antibiotics and implant retention; IQR=interquartile range; N, number; PJI, periprosthetic joint infection; SD, standard 
deviation; *, do not add up to the total number of participants or infections as some studies did not report these data 
 
 
 
 
 
 
 
 
 
 
 
